NCI Announces New Cancer Survivorship Training Program
In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues survivors face.
In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues survivors face.
The training program was developed by NCIs Office of Cancer Information, Communication, and Education in collaboration with Ortho Biotech Inc., the National Coalition for Cancer Survivorship, and cancer organizations nationwide.
To obtain a free copy of the training program, please contact the NCIs Cancer Information Service at 1 (800) 4-CANCER [1 (800) 422-6237].
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
